Rare 2030 Action Campaign Pushing for European Plan for Rare Diseases

Work Stops on Fezagepras, or PBI-4050, as Potential IPF Treatment

Liminal BioSciences is stopping the clinical development of its investigative oral therapy fezagepras (PBI-4050) for idiopathic pulmonary fibrosis (IPF), based on interim pharmacological data from a Phase 1 clinical trial testing it at ascending doses in healthy volunteers. The decision comes less than a month after the company announced plans…

First IPF Patient Enrolled in Phase 3 Study of Tyvaso

The first participant has been enrolled in a Phase 3 trial to evaluate the impact of United Therapeutics’ Tyvaso (inhaled treprostinil) on lung function in adults with idiopathic pulmonary fibrosis (IPF). The trial, TETON (NCT04708782), aims to recruit approximately 396 people ages 40 and older, who…

Where Do We Turn When Prescribed Therapies Aren’t Effective?

Managing symptoms is an ongoing challenge for chronically ill patients. Whether they’re caused by an exacerbation, disease progression, or environmental factors, it’s often difficult for patients to get quick relief, including from respiratory symptoms. Despite their name, rescue inhalers aren’t always effective in managing or improving pulmonary fibrosis…

Remembering My Mother, a Pillar on My Support Team

One of the most important blessings in life is having a strong support group. A support team may consist of family members, friends, or a community of people. My support team included three of the greatest people in my life: my husband, daughter, and mother. It is important…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums